CSL logo
CSL
CMXHF | OTC
Chart Builder DCF Calculator
$127.68
+$0.18 (+0.14%)
At close: Oct 5, 2026, 4:00 PM ET

CSL Company Profile

Company profile explained

Company Profile

CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company's activities are organized into two primary divisions: CSL Behring and Seqirus. CSL Behring specializes in plasma-derived therapies, delivering essential plasma products and recombinant treatments designed to manage a range of serious conditions such as immunodeficiencies, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. Beyond its therapeutic offerings, this division actively pursues research in both plasma and non-plasma-based treatments, and also generates revenue through licensing and royalties from its intellectual property commercialization. Meanwhile, Seqirus focuses on the manufacturing and distribution of non-plasma biotherapeutics, alongside the development of innovative influenza vaccines and related products. Established in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

Key Executives

Name Position
Gordon Naylor DipCompSc MD, Chief Executive Officer & Executive Director
Amy Van Buren Chief People Officer
Ken Lim Chief Financial Officer
Deirdre BeVard Senior Vice President of Research & Development Strategic Operations
Gregory Boss Executive VP of Legal & Group General Counsel
Herve Gisserot Executive VP of Business Development & Enterprise Alliance Management
Kate Sophie Priestman Chief Corporate & External Affairs Officer
Mark Dehring Head of Investor Relations
Mark Hill Chief Digital Information Officer & Executive Vice President
Mary Oates Executive VP & COO
Michelle Rees Head of Investor Relations
Stephen Marlow Executive VP & GM of CSL Plasma
William Mezzanotte Chief Medical Officer, Executive Vice President and Head of Research & Development
CSL
CSL logo
Country Australia
IPO Date Nov 18, 2005
Industry Biotechnology
Sector Healthcare
Employees 29,000
CEO Gordon Naylor DipCompSc

Contact Details

655 Elizabeth Street Melbourne, VIC 3000 Australia

Stock Details

Ticker Symbol CMXHF
Exchange OTC
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001274152
CUSIP Number n/a
ISIN Number AU000000CSL8
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.